Sanofi has received a "Buy" rating from UBS, with a target price of 110 euros, after reporting its third-quarter results.
Analyst Jo Walton noted that Sanofi's sales exceeded both his and market consensus estimates, driven by strong vaccine sales.
The report, published on October 25, 2024, suggests a positive outlook for Sanofi, indicating strong performance in the pharmaceutical sector.
Investors are optimistic about the company's ability to outperform in a competitive market.